Possible scenario
Novo gains edge
38% Chance
Investors treat the 6% heart-risk advantage as a meaningful differentiator for Novo Nordisk in high-risk diabetes and obesity patients. The result reinforces Novo's cardiovascular-outcomes narrative after prior Wegovy data and puts incremental pressure on Eli Lilly's Mounjaro positioning.
Secondary impacts
- Healthcare +0.4%
Tickers
- LLY-3.3%
- CVS+0.4%
- UNH+0.3%
Portfolio impact
S&P 500-0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.